Cyxone signs new co-operation agreement with Bachem of Switzerland

Since 2016, Cyxone AB and Swiss pharmaceutical manufacturer Bachem AG have worked closely on the production of syntheses of Cyxone's development substance T20K, and on the production of substances for studies that started last year.

Today, Cyxone and Bachem have signed an agreement to further develop T20K, produce necessary reference substances, and manufacture sufficient amounts of test substances for the company's cell- and animal trials and GMP-certified T20K for clinical studies. The co-operation agreement will run for around one year and have a total budget of SEK 2.5 milion kronor.

"Through this co-operation agreement with Bachem, one of the world's leading drug manufacturers, we feel confident of obtaining high quality T20K for Cyxone's continued development work," says Kjell G. Stenberg, Cyxone CEO.

May 15, 2017

For more information, please contact:

Cyxone AB (publ.)
Kjell G. Stenberg, CEO
Tel: +46 (0) 723 816 168
Email: kjell.g.stenberg@cyxone.com
Adelgatan 21
211 22 Malmö
cyxone.com

About Cyxone 
Cyxone AB (publ.) is a biopharmaceutical company that develops drugs based on cyclotides, a class of natural plant protein. Cyclotide technology has the potential to provide new drugs with beneficial pharmacological effects on diseases that currently lack safe and effective treatments. The company is focusing on the development of T20K, a substance that inhibits key processes in cells that are typically associated with various immune disorders, such as multiple sclerosis and rheumatoid arthritis. Cyxone's Certified Adviser on the Nasdaq First North is Erik Penser Bank.